micro-community-banner
 
Profile Image
  • Saved
Lipid Nanovesicles in Cancer Treatment: Improving Targeting and Stability of Antisense Oligonucleotides - PubMed

Lipid Nanovesicles in Cancer Treatment: Improving Targeting and Stability of Antisense Oligonucleotides - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/39967902/

Cancer remains a leading cause of mortality worldwide, accounting for approximately 10 million deaths annually. Standard treatments, including surgery, radiotherapy, and chemotherapy, often result in damage to healthy cells and...

Lipid nanovesicles improve ASO cancer therapy by enhancing targeting, stability, and half-life, reducing toxicity, and boosting efficacy, though delivery challenges remain.

 

Profile Image
  • Saved

pt after mi ldl below 55 can be obtain with statin and pck 9 inhibitor comfotably if insurance covers pck inhibitor

Profile Image
  • Saved

goal after cardivascular surgery is to get ldl below 55 without side effects on statins,if it cannot be achieve on statin alone,add zetia,or pck 9 inhibitors or nexlizet

Profile Image
  • Saved

Post-MI lipid management includes a discussion about LDL targets and use of high-dose, high-potency statins and behavioral/lifestyle changes to attain LDL goal. Reevaluation of lipids 3 months later commences with additional methods to lower LDL introduced then, as needed and this may include additional medications.

Profile Image
  • Saved

post mi, I am part of the team that gets consulted on lipid management as well as a nutrition consult is generated. If LDLc is not within guidelines of AHA or NLA ( at least less than 70 mg/dl) I add PCSK9i for LDLc normalization as well as plaque regression post MI leaving the maximally tolerated statin plus/minus ezetimibe on board .

Profile Image